Thursday, April 9, 2020
CytoDyn Applies for Clinical Trial of Its AIDS Treatment as Drug for COVID-19
A CMO Partner of Samsung Biologics
CytoDyn Applies for Clinical Trial of Its AIDS Treatment as Drug for COVID-19
  • By Choi Moon-hee
  • March 11, 2020, 11:51
Share articles

CytoDyn, a Vancouver-based biotech company which signed a manufacturing contract with Samsung Biologics last year, is planning to carry out a clinical test on a potential covid-19 treatment.

Samsung Biologics signed a contract manufacturing organization (CMO) agreement on Leronlimab (PRO 140), an AIDS treatment from the Canadian company, in April last year. Leronlimab is being developed as a treatment for AIDS and cancer. As the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for Leronlimab in May 2019, the treatment was registered with the FDA after Phase III clinical trials.

CytoDyn recently decided to conduct a clinical trial of Leronlimab as a treatment for the COVID-19 virus as AIDS treatments have been used for COVID-19 patients.

CytoDyn submitted to the FDA an investigational new drug application (IND) for Phase II clinical trial of Leronlimab as a treatment for patients suffering from respiratory complications after being infected with the COVID-19 virus.